|2.||Urinary Bladder Neoplasms (Bladder Cancer)
|3.||Neoplasm Metastasis (Metastasis)
|5.||Prostatic Neoplasms (Prostate Cancer)
|1.||Shariat, Shahrokh F: 119 articles (02/2016 - 03/2002)|
|2.||Grossman, H Barton: 89 articles (04/2015 - 06/2002)|
|3.||Lotan, Yair: 82 articles (02/2016 - 01/2002)|
|4.||Lerner, Seth P: 71 articles (01/2016 - 03/2002)|
|5.||Kamat, Ashish M: 69 articles (11/2015 - 02/2002)|
|6.||Kassouf, Wassim: 66 articles (09/2015 - 12/2004)|
|7.||Kim, Wun-Jae: 60 articles (12/2015 - 11/2004)|
|8.||Karakiewicz, Pierre I: 55 articles (09/2014 - 02/2005)|
|9.||Dinney, Colin P: 52 articles (11/2015 - 04/2003)|
|10.||Herr, Harry W: 50 articles (06/2015 - 03/2002)|
|1.||Cisplatin (Platino)FDA LinkGeneric
02/01/1984 - "We conclude that intra-arterial cisplatin can be highly effective for localized invasive bladder cancer even when relatively low doses are used. "
01/01/1990 - "This combined therapy of cisplatin and radiation is very effective for invasive bladder cancer."
07/01/2014 - "In this current study, we found low expression of UNC5A in bladder cancer, an effective induction of UNC5A by cisplatin in bladder cancer cell lines with wt p53, and a significant reduction of cisplatin-mediated cell death following silencing the endogenous UNC5A. "
02/01/2001 - "Concomitant cisplatin and irradiation improved the control of locally advanced bladder cancers, but failed to improve overall survival. "
11/01/1996 - "Concurrent cisplatin may improve pelvic control of locally advanced bladder cancer with preoperative or definitive radiation, but has not been shown to improve overall survival. "
|2.||Mitomycin (Mitomycin-C)FDA LinkGeneric
09/01/2011 - "Bladder cancer: EMDA mitomycin before TURBT is the best treatment for non-muscle-invasive disease."
01/01/1992 - "at the dose of 50 micrograms per animal per day during 6-week period of promotion with mitomycin C, the incidence of urinary bladder cancer was dramatically reduced. "
08/01/2015 - "This study sought to determine if the addition of perioperative mitomycin C (MMC) to treatment with bacillus Calmette-Guérin (BCG) after transurethral resection (TURBT) is superior to TURBT plus BCG alone in high grade non-muscle invasive bladder cancer (NMIBC). "
03/01/2004 - "Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials."
11/01/1998 - "We study toxicity and efficacy of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin (BCG) in patients with intermediate or high risk superficial bladder cancer compared to the use of intravesical mitomycin C alone. "
08/01/2002 - "Concomitant chemo-radiation using gemcitabine as a radiosensitizer have been shown to be highly effective in pancreatic and in bladder cancer and deserve further investigation. "
04/15/2010 - "The efficacy of intravesical gemcitabine was evaluated compared with repeated administration of bacille Calmette-Guérin (BCG) after BCG failure in high-risk, non-muscle-invasive bladder cancer (BC). "
01/01/2010 - "To evaluate the safety, tolerability and efficacy of adjuvant intravesical gemcitabine versus bacillus Calmette-Guérin (BCG) in the treatment of high-risk superficial bladder cancer. "
06/01/2013 - "To investigate the therapeutic efficacy of double-mutated oncolytic adenovirus AxdAdB-3 in combination with gemcitabine for treating bladder cancer in an orthotopic nude mouse model. "
09/01/2009 - "Recurrence prophylaxis with intravesical gemcitabine (GEM) was effective and safe in patients with non-muscle-invasive bladder cancer (NMIBC); efficacy as single-shot instillation remains to be proved. "
|4.||Epirubicin (Ellence)FDA LinkGeneric
01/01/1996 - "A prospective randomized trial on 94 eligible patients evaluated and compared the efficacy of adjuvant intravesical epirubicin and bacillus Calmette-Guérin (BCG) after complete resection of multifocal superficial bladder cancer. "
09/01/1993 - "A controlled prospective trial involving 161 patients evaluated and compared the efficacy of intravesical epirubicin and bacillus Calmette-Guérin (BCG) administration as prophylaxis against recurrences after complete transurethral resection of superficial bladder cancer. "
07/01/2008 - "The present study showed no statistically significant differences in terms of disease-free time and recurrence rate between high risk patients with nonmuscle invasive bladder cancer who had undergone perioperative epirubicin instillation plus delayed bacillus Calmette-Guerin and those who had undergone delayed bacillus Calmette-Guerin alone."
06/01/2000 - "Because the efficacy of combination was no better than the standard treatment and the alternating combination seemed to be related to a higher incidence of side-effects, this study albeit small, does not recommend combination therapy of BCG and epirubicin in high risk patients with superficial bladder cancer."
01/01/1998 - "A prospective randomized study was undertaken to determine whether prophylactic maintenance instillation of epirubicin following induction treatment is beneficial in patients with superficial bladder cancer. "
|5.||Doxorubicin (Adriamycin)FDA LinkGeneric
01/01/1997 - "The observed high complete response and good survival rate suggest that intraarterial CDDP and doxorubicin might be highly effective for localized invasive bladder cancer."
02/01/2014 - "Combination therapy with GC7 may enhance the therapeutic efficacy of doxorubicin in bladder cancer by inhibiting eIF5A2 activation and preventing epithelial-mesenchymal transition. "
01/01/1987 - "These preliminary results suggest that preoperative doxorubicin instillation might be effective for prolongation of the disease-free interval in patients with recurrent bladder cancer."
05/01/2005 - "Adjuvant intravesical doxorubicin could not be shown to improve recurrence, progression and survival of superficial bladder cancer, compared with control on long-term follow-up. "
08/01/2015 - "In this study, we want to explore the relationship among nucleophosmin1, drug resistance, and recurrence of bladder cancer, using normal bladder epithelia cell line SV-HUC-1, bladder cancer cell lines PUMC-91, PUMC-91 against gradient doses of adriamycin (0.3, 0.6, and 1.0 μg/ml), and bladder cancer tissue samples. "
|6.||Biological Markers (Surrogate Marker)IBA
05/01/2000 - "Further research and better understanding of the biology of bladder cancer, improved diagnostic techniques, and standardized interpretation are essential steps to develop reliable biomarkers. "
01/01/2014 - "Several gene-based urinary biomarkers have demonstrated promise in initial studies, which now need to be rigorously validated in the clinical setting for them to be translated into clinically useful tests in diagnosis, surveillance or risk-stratification of bladder cancer."
10/01/2014 - "In conclusion, combined use of the cytology with the studied biomarkers can improve the sensitivity for detecting bladder cancer, and may be very useful in monitoring the effectiveness of antiangiogenic and apoptotic therapies in bladder cancer."
03/01/2015 - "This review discusses the efficacy of such biomarkers as well as highlights some potential prognostic markers in the field of noninvasive bladder cancer detection. "
12/15/2015 - "Urinary biomarkers miss a substantial proportion of patients with bladder cancer and are subject to false-positive results in others. "
|7.||Methotrexate (Mexate)FDA LinkGeneric
09/01/1988 - "Our results show that methotrexate injection is highly effective in the treatment of advanced bladder cancer. "
08/01/1991 - "The experimental and clinical studies were performed to investigate the efficacy of the anal submucosal injection (ASI) of methotrexate (MTX) for bladder cancer. "
08/01/1991 - "[Experimental and clinical studies on anal submucosal injection of methotrexate for bladder cancer]."
01/01/1986 - "Phase I/II trial of intravesical methotrexate for superficial bladder tumors."
02/01/1984 - "As part of a phase III study in advanced bladder cancer, 5 patients received methotrexate (MTX) 50 mg/m2 as a single agent every 2 weeks, and with every alternate dose of MTX (i.e. "
12/01/1997 - "Recent studies suggest that the bladder tumor antigen (BTA) test, an agglutination reaction for basement membrane complexes, is superior to voided urine cytology in clinical practice. "
11/01/1987 - "The bladder cancer group demonstrated 8/9 positive results for relative antigen concentrations greater than 3.0. "
11/01/2002 - "A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results."
11/01/2001 - "A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results."
01/01/2015 - "Several studies reported Prostate stem cell antigen (PSCA) rs2294008 was susceptibly associated with bladder cancer (BC) risk. "
|9.||nuclear matrix protein 22IBA
04/01/2000 - "The purpose of this study was to evaluate, from the perspective of the Quebec health system, the cost and cost-efficacy of using NMP22 compared with the currently recommended monitoring procedure following a transurethral resection of a bladder tumor (TURBT). "
12/01/2008 - "Combining NMP22 with malignant or suspicious cytological result improved sensitivity for the detection of bladder cancer but with a major decrease in specificity, suggesting a potential role in screening rather than diagnosis."
03/01/2006 - "The NMP22 BladderChek test is an in vitro qualitative test that is easily available and cheap; it can be performed by a urologist in the office and results can be interpreted within 30 min. The NMP22 test is superior to cytology for all grades and stages in the detection of recurrence in patients with a history of superficial bladder cancer. "
03/01/2011 - "The NMP22 test may be considered a new gold standard for the assessment of patients with known or suspected bladder cancer."
09/01/2013 - "In this study, we investigated the efficacy of nuclear matrix protein 22 (NMP22) in the diagnosis and surveillance of bladder cancer. "
|10.||Vinblastine (Vinblastine Sulfate)FDA Link
04/01/2005 - "Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer."
01/01/2015 - "To differentiate and delineate the molecular events, we developed drug resistant human transitional bladder cancer T24 cells (DRC) by treating cells with the increasing concentration of vinblastine. "
01/01/2015 - "Molecular events are associated with resistance to vinblastine in bladder cancer."
12/15/1992 - "Concurrent vinblastine and radiation therapy in bladder cancer."
04/01/1985 - "Vinblastine and methotrexate for advanced bladder cancer."
09/01/2015 - "Radical cystectomy (RC) represents the mainstay of treatment in patients with muscle-invasive urinary bladder cancer but how it compares with the best organ preservation approach is not known. "
04/01/2012 - "Our results support the use of cystectomy in octogenarians with invasive bladder cancer, which has acceptable morbidity and mortality, and offers the best chance for sustained disease-free quality survival."
03/01/2011 - "radical cystectomy remains the most effective treatment for patients with localized, invasive bladder cancer and recurrent noninvasive disease. "
06/01/2010 - "While radical cystectomy, the best treatment option for local control of bladder cancer, has been shown to be safe in the elderly, outcomes depend more heavily on the functional status of the patient than on chronologic age. "
02/01/2010 - "Radical cystectomy remains the most effective treatment for patients with localized, invasive bladder cancer and recurrent noninvasive disease. "
|2.||Drug Therapy (Chemotherapy)
01/01/2011 - "Superficial, noninvasive bladder cancer can most often be cured; a good proportion of invasive cases can also be cured by a combined modality approach of surgery, chemotherapy, and radiation. "
08/01/1984 - "Intravesical chemotherapy is one of the most effective treatments for superficial bladder tumors. "
08/01/2014 - "Intravesical chemotherapy is beneficial for patients with non-muscle-invasive bladder cancer (NMIBC), but optimal drug and regimen selection can be controversial. "
12/01/2013 - "Accurate preoperative prediction of survival is considered important because neoadjuvant chemotherapy may be as effective for high-risk UUT-UC as for muscle-invasive bladder cancer. "
03/01/2011 - "Accordingly it is important to be able to predict whether a regimen is effective in each patient with bladder cancer before the initiation of chemotherapy. "
10/01/2008 - "Intravesical instillation of BCG is the most effective in the long term when chosen as the initial prophylactic therapy for the prevention of recurrence in superficial bladder cancer."
07/01/2006 - "Intravesical instillation of Bacillus Calmette-Guérin (BCG) after transurethral resection is the most effective treatment for superficial bladder cancers. "
06/01/2003 - "The data suggest that intravesical instillation of BCG is more effective when no prior treatment has been attempted, and that best results may be achieved if BCG is chosen as the initial therapy for superficial bladder cancer. "
12/01/1990 - "Intravesical administration of bacillus Calmette-Guerin has been shown to be highly effective treatment of superficial bladder cancer. "
10/01/1986 - "Intravesical instillation of bacille Calmette Guerin (BCG) currently is considered the most effective treatment for recurrent superficial bladder cancer, but little is known about the mechanism of action. "
03/01/2001 - "Our previous animal studies demonstrated that aged garlic extract was highly effective, and unlike the approved immunotherapy for human bladder cancer, bacillus Calmette--Guérin (BCG), garlic was effective when added to the diet. "
03/01/2015 - "Adjuvant immunotherapy of bladder cancer by instillation of bacillus Calmette-Guérin (BCG) is highly recommended within certain groups of non-muscle-invasive stages but only partially effective. "
01/01/1990 - "As bacillus Calmette-Guérin (BCG) immunotherapy is highly effective for most but not all superficial bladder tumors, there is a need to define predictors of response to this mode of treatment. "
04/01/2001 - "The use of BCG immunotherapy, a very major advance in the management of superficial bladder cancer, is limited by the frequency of adverse events. "
12/01/2015 - "In this study, it was clearly observed that cationic CS nanoparticles provide a significantly improved perspective in intravesical immunotherapy of bladder tumors."
08/01/2008 - "Although direct comparison of surgically based and radiotherapy-based approaches would be very useful, it is highly unlikely that such a trial could ever be completed among the patients treated by the clinicians who routinely deal with invasive bladder cancer."
01/01/1977 - "The best results of treatment for recurrent bladder cancer were gained in the combination therapy (surgery and radiotherapy) and also while using distant gammatherapy."
11/01/2014 - "In our model, adaptive radiotherapy techniques for canine bladder cancer showed significant reduction in rectal volume irradiated when compared to nonadaptive techniques, while maintaining appropriate bladder coverage."
03/01/1994 - "It was concluded that high dose rate intracavitary radiotherapy was a useful treatment for CIS of the bladder and superficial bladder cancer."
07/01/2003 - "To evaluate the feasibility and efficacy of a concomitant partial bladder boost schedule in radiotherapy for invasive bladder cancer, coupling a limited boost volume with shortening of the overall treatment time. "